Effect of phosphodiesterase inhibitors on heart contractile behaviour, protein kinase activity and cyclic nucleotide levels.
D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000378:metabolism*; D009712:Nucleotides, Cyclic / Q000378:metabolism*; D010208:Papaverine / Q000494:pharmacology; D010431:Pentoxifylline / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000378:metabolism*; D051381:Rats; D013806:Theophylline / Q000494:pharmacology
D009712:Nucleotides, Cyclic; D010726:Phosphodiesterase Inhibitors; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D011494:Protein Kinases; D006152:Cyclic GMP; D010431:Pentoxifylline